|
|
Vaccine Detail
|
AE37 Peptide/GM-CSF Vaccine |
| Vaccine Information |
- Vaccine Name: AE37 Peptide/GM-CSF Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007212
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: ERBB2
- GM-CSF (human)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- ERBB2
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Adjuvant:
- Adjuvant name:
- VO adjuvant ID: VO_0001294
- Description: GM-CSF vaccine adjuvant
- Preparation: AE37 is a novel peptide that is a hybrid of the naturally occurring HER2-derived peptide AE36 (HER2:776–790) generated by the addition of the Ii-key peptide (LRMK) to the N terminal (Mittendorf et al., 2011).
- Description: A vaccine containing HER2/Neu-derived epitope (amino acids 776-790) linked to li-Key peptide (li-Key/HER2/neu hybrid peptide or AE37), and combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunoadjuvant activities. Upon vaccination, AE37 may activate the immune system and stimulate T-helper cells against HER2/Neu expressing cancer cells. GM-CSF may potentiate the immune response against cancer cells expressing the HER2/Neu antigen. The Ii-Key moiety, a 4-amino acid (LRMK) epitope from the MHC class II-associated invariant chain (Ii protein), increases T-helper cell stimulation against HER2/neu antigen when compared to unmodified class II epitopes. HER2/neu, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types and is highly immunogenic. This vaccine is used in clinical trials involving breast cancer patients to prevent recurrence (Brown et al., 2020; NCIT_C91719).
|
| Host Response |
|
|
| References |
Brown et al., 2020: Brown TA 2nd, Mittendorf EA, Hale DF, Myers JW 3rd, Peace KM, Jackson DO, Greene JM, Vreeland TJ, Clifton GT, Ardavanis A, Litton JK, Shumway NM, Symanowski J, Murray JL, Ponniah S, Anastasopoulou EA, Pistamaltzian NF, Baxevanis CN, Perez SA, Papamichail M, Peoples GE. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast cancer research and treatment. 2020; 181(2); 391-401. [PubMed: 32323103].
Mittendorf et al., 2011: Mittendorf EA, Alatrash G, Xiao H, Clifton GT, Murray JL, Peoples GE. Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials. Expert review of vaccines. 2011; 10(6); 755-774. [PubMed: 21692698].
NCIT_C91719: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91719]
|
|
